Prediabetes Pipeline Insight

DelveInsight’s, "Prediabetes - Pipeline Insight, 2023,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Prediabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Prediabetes Understanding

Prediabetes: Overview

Prediabetes is a metabolic disorder that is considered as a precursor for the development of diabetes mellitus. It is characterized by higher than normal blood glucose levels that has not yet reached diabetic levels. Prediabetes is also called impaired glucose tolerance or impaired fasting glucose. Most people who get type 2 diabetes have prediabetes first. About 5-10% of individuals with the condition of prediabetes or intermediate hyperglycemia develop diabetes annually. However, Prediabetes can revert to normal glycemic state as well, with proper lifestyle changes.

The exact cause of prediabetes is unknown, but family history and genetics appear to play an important role. A lack of regular physical activity and being overweight with excess fat also seem to be an important factors. Prediabetic persons also doesn’t make or use the hormone insulin properly, as a result, too much glucose builds up in the bloodstream. This buildup of sugar in the blood causes prediabetes

"Prediabetes - Pipeline Insight, 2023" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Prediabetes pipeline landscape is provided which includes the disease overview and Prediabetes treatment guidelines. The assessment part of the report embraces, in depth Prediabetes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Prediabetes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence R&D Prediabetes. The therapies under development are focused on novel approaches to treat/improve Prediabetes.

Prediabetes Emerging Drugs

Apabetalone: Resverlogix

Apabetalone (RVX-208) is a first-in-class, small molecule selective BET bromodomain inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can turn disease-causing genes off and returning them to a healthier state. Apabetalone is the first and only BET inhibitor selective for BRD4-BD2, producing a nexus of biological effects with potentially important benefits for patients with diseases such as cardiovascular disease (CVD), diabetes mellitus (DM), Alzheimer's disease, peripheral artery disease, and chronic kidney disease while maintaining an excellent safety profile.

BTI-320: Boston Therapeutics

BTI-320 is a non-systemic, non-toxic, chewable investigative candidate for prevention or delay of diabetes. Also first line for reversal of prediabetes. BTI-320 inhibits the enzymes that release glucose from complex carbohydrate in foods during digestion, reducing the amount of available glucose absorbed through the intestine. BTI-320 is a safe and effective drug compound for people with pre-diabetes and diabetes in their daily management of blood glucose levels.

Further product details are provided in the report……..

Prediabetes: Therapeutic Assessment

This segment of the report provides insights about the Prediabetes drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Prediabetes

There are approx. 15+ key companies which are developing the therapies Prediabetes. The companies which have their Prediabetes drug candidates in the most advanced stage, i.e Phase II include, Boston Therapeutics

Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Prediabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Prediabetes: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Prediabetes therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Prediabetes drugs.

Prediabetes Report Insights

• Prediabetes Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Prediabetes Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Prediabetes drugs?
• How many Prediabetes drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Prediabetes?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Prediabetes therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Prediabetes and their status?
• What are the key designations that have been granted to the emerging drugs?